Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the United States

By sjmartinez • November 15, 2022

Turbyfill C, Adams K, Tenforde MW, Murray NL, Gaglani M, Ginde AA, McNeal T, Ghamande S, Douin DJ, Keipp Talbot H, Casey JD, Mohr NM, Zepeski A, Shapiro NI, Gibbs KW, Clark Files D, Hager DN, Shehu A, Prekker ME, Frosch AE, Exline MC, Gong MN, Mohamed A, Johnson NJ, Srinivasan V, Steingrub JS, Peltan ID, Brown SM, Martin ET, Lauring AS, Khan A, Busse LW, Ten Lohuis CC, Duggal A, Wilson JG, June Gordon A, Qadir N, Chang SY, Mallow C, Rivas C, Kwon JH, Halasa N, Chappell JD, Grijalva CG, Rice TW, Stubblefield WB, Baughman A, Rhoads JP, Lindsell CJ, Hart KW, McMorrow M, Surie D, Self WH, Patel MM. Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the United States. Vaccine. 2022 Nov 15;40(48):6979-6986. doi: 10.1016/j.vaccine.2022.10.034. Epub 2022 Oct 24. PMID: 36374708.

Tags: case-control study, Control groups, covid-19, Publications, Pulmonary, Critical Care & Sleep Medicine, Research design, Test-negative, vaccine effectiveness

Related Posts

Early cellular events of osteomucosal healing in the tooth extraction socket

Kim S, Song M, Williams D, Du W, Cho I, Bae E, Kim J, Goswami A, Shin KH, Park NH, Kim RH. Early cellular events[...]

Ventricular Tachycardia Predicts All-Cause Mortality and Nonsudden Cardiac Death in Nonischemic Cardiomyopathy

Omara S, Jensen TN, Koeber L, Thune JJ, Pehrson S, Mertens B, Tedrow UB, Hindricks G, Ebert M, Carbucicchio C, Berruezo A, Vaseghi M, Shivkumar[...]

A treatment-impact model of alectinib for the prediction of recurrence and associated costs in treating resectable ALK+ non-small cell lung cancer

Cummings AL, Sussell J, Rosettie KL, Moustaid FE, Ogale S, Ngiam C, Jovanoski N, Arnold M, Lee JM. A treatment-impact model of alectinib for the[...]